期刊文献+

脑胶质瘤Apaf-1基因表达及启动子区甲基化的研究

原文传递
导出
摘要 胶质瘤是一种最常见的颅内肿瘤,其发生率占全部颅内肿瘤的40%,即便采取手术切除、放化疗等综合治疗,仍预后不良。近年来已经有相当多的研究发现胶质瘤细胞存在多种凋亡基因异常,提示胶质瘤细胞存在凋亡通路功能异常,研究有关凋亡的变化可能为探讨胶质瘤的发生提供线索。人凋亡蛋白酶活化因子-1(apoptotic protease activating factor-1,Apaf-1)基因位于染色体12q23,Apaf-1和Caspase-9是c-Myc诱导细胞凋亡中p53的下游成分,是线粒体凋亡途径的一个关键调节因子。我们研究Apaf-1基因在胶质瘤中的表达及启动子甲基化情况,探讨该基因与胶质瘤发生和发展的关系。为研究颅内肿瘤的基因诊断和基因治疗提供依据。
出处 《中华神经外科杂志》 CSCD 北大核心 2008年第5期376-379,共4页 Chinese Journal of Neurosurgery
  • 相关文献

参考文献13

  • 1段国升.脑胶质瘤临床治疗的进展[J].中华神经外科杂志,2004,20(2):85-87. 被引量:49
  • 2于士柱,孙兆明.胶质瘤细胞增殖及凋亡调控紊乱研究的进展[J].中华病理学杂志,2005,34(9):547-549. 被引量:5
  • 3Steinbach JP, Weller M. Apoptosis in gliomas: molecular mechanisms and therapeutic implications. J Neurooncol, 2004,70 : 245 -254.
  • 4史怀璋,李钰,刘晓谦,宋学明,胡韶山,高成,吕冰洁,谢向晨,岳武.p53基因、PTEN基因协同对胶质瘤U251细胞系生长抑制作用的研究[J].中华神经外科杂志,2004,20(1):22-25. 被引量:7
  • 5Campioni M, Santini D, Tonini G . Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol, 2005,14 : 811-818.
  • 6Soengas MS, Capodieci P, Polsky D,et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature,2001, 409:207-211.
  • 7Zou H, Henzel WJ, Liu XS, et al . Apaf-1, a human protein homologous to C.elegans CED-4,participates in cytochrome c-dependent activation of caspase-3.Cell,1997,90:405-413.
  • 8Cain K,Bratton SB,Langlais C.Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1,4-MDa apoptosome complexes.J Biol Chem,2000,275:6067-6070.
  • 9Lauber K,Appel HA,Schlosser SF.The adapter protein apoptotic protease-activiating factor-1 (Apaf-1)is proteolytically processed during apoptosis .J Biol Chem,2001,276:29772-29781.
  • 10杨振华,蔡映云,于坚,揭志军,朱景德.肿瘤相关基因启动子甲基化在非小细胞肺癌细胞株中的作用研究[J].中国实用内科杂志:临床前沿版,2006,26(5):746-748. 被引量:4

二级参考文献47

  • 1Calogero A, Arcella A, De Gregorio G, et al. The early growth response gene EGR-1 behaves as a suppressor gene that is downregulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin Cancer Res, 2001, 7 : 2788-2796.
  • 2Watanabe T, Katayama Y, Yoshino A, et al. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res,2003, 9 : 4884-4890.
  • 3Watanabe T, Nakamura M, Yonekawa Y, et al. Promoter hypermethylation and homozygous deletion of the pl4ARF and p16INK4a genes in oligodendrogliomas. Aeta Neuropathol ( Berl),2001, 101 : 185-189.
  • 4Perry A, Anderl K, Borell TJ, et al. Detection of pl6, RB, CDK4,and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am J Clin Pathol, 1999, 112: 801-809.
  • 5Suzuki T, Maruno M, Wada K, et al. Genetic analysis of human glioblastomas using a genomic microarray system. Brain Tumor Pathol, 2004, 21: 27-34.
  • 6Nishikawa R, Sugiyama T, Nafita Y, et al. Immunohistochemical analysis of the mutant epidermal growth factor, delta EGFR, in glioblastoma. Brain Tumor Pathol, 2004, 21 : 53-56.
  • 7Mizoguchi M, Nutt CL, Mohapatra G, et al. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas.Brain Pathol, 2004, 14 : 372-377.
  • 8Fiano V, Ghimenti C, Imarisio S, et al. PAkt, cyclin D1 and p27/Kipl in glioblastomas with and without EGFR amplification and PTEN mutation. Anticancer Res, 2004, 24(5A) : 2643-2647.
  • 9Park KH, Lee J, Yoo CG, et al. Application of p27 gene therapy for human malignant glioma potentiated by using mutant p27. J Neurosurg, 2004 , 101: 505-510.
  • 10Cheung KJ Jr, Li G. The tumor suppressor ING1: structure and function. Exp Cell Res, 2001, 268: 1-6.

共引文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部